Multicenter trial of fluoxetine as an adjunct to behavioral smoking cessation treatment
Department of Medicine, Division of Preventive and Behavioral Medicine
Adult; Behavior Therapy; Combined Modality Therapy; Double-Blind Method; Female; Fluoxetine; Humans; Male; Serotonin Uptake Inhibitors; Smoking; *Smoking Cessation
Life Sciences | Medicine and Health Sciences | Women's Studies
The authors evaluated the efficacy of fluoxetine hydrochloride (Prozac; Eli Lilly and Company, Indianapolis, IN) as an adjunct to behavioral treatment for smoking cessation. Sixteen sites randomized 989 smokers to 3 dose conditions: 10 weeks of placebo, 30 mg, or 60 mg fluoxetine per day. Smokers received 9 sessions of individualized cognitive-behavioral therapy, and biologically verified 7-day self-reported abstinence follow-ups were conducted at 1, 3, and 6 months posttreatment. Analyses assuming missing data counted as smoking observed no treatment difference in outcomes. Pattern-mixture analysis that estimates treatment effects in the presence of missing data observed enhanced quit rates associated with both the 60-mg and 30-mg doses. Results support a modest, short-term effect of fluoxetine on smoking cessation and consideration of alternative models for handling missing data.
DOI of Published Version
J Consult Clin Psychol. 2002 Aug;70(4):887-96.
Journal of consulting and clinical psychology
Niaura R, Spring B, Borrelli B, Hedeker D, Goldstein MG, Keuthen NJ, DePue J, Kristeller JL, Ockene JK, Prochazka A, Chiles JA, Abrams DB. (2002). Multicenter trial of fluoxetine as an adjunct to behavioral smoking cessation treatment. Women’s Health Research Faculty Publications. https://doi.org/10.1037/0022-006X.70.4.887. Retrieved from https://escholarship.umassmed.edu/wfc_pp/402